{"id":"NCT02023164","sponsor":"JDP Therapeutics, Inc.","briefTitle":"Pilot Phase III Clinical Trial of JDP-205 IV Injection for Treatment of Acute Urticaria","officialTitle":"Multicenter Pilot Study to Assess the Feasibility of Conducting Phase III Trial Comparing IV Cetirizine Injection, 10 mg, to IV Diphenhydramine, 50 mg, for The Treatment of Acute Urticaria","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-07","primaryCompletion":"2014-12","completion":"2014-12","firstPosted":"2013-12-30","resultsPosted":"2024-02-09","lastUpdate":"2024-02-09"},"enrollment":36,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acute Urticaria"],"interventions":[{"type":"DRUG","name":"JDP-205 Injection","otherNames":["Cetirizine","Quzyttir"]},{"type":"DRUG","name":"Diphenhydramine","otherNames":["Benadryl","DPH"]}],"arms":[{"label":"Test Drug","type":"EXPERIMENTAL"},{"label":"Control","type":"ACTIVE_COMPARATOR"}],"summary":"This is a multicenter, parallel group, randomized, double-blind pilot Phase III clinical study of JDP-205 (cetirizine) injection, versus diphenhydramine injection, 50 mg/mL (Benadryl or generic equivalent), in approximately 36 patients with acute urticaria requiring treatment in Hospital Emergency Departments, Urgent Care Centers and Allergy Clinics.","primaryOutcome":{"measure":"Extent of Urticaria/Erythema Score (Physician Assessment)","timeFrame":"Baseline, 1 hour, 2 hour, Discharge (up to 4 hours)","effectByArm":[{"arm":"Test Drug","deltaMin":1.91,"sd":0.61},{"arm":"Control","deltaMin":1.74,"sd":0.89}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":18},"locations":{"siteCount":6,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":["Rash pruritic","Rash","Urticaria","Pruritis","Dizziness"]}}